UROsphere, Faculté des Sciences Pharmaceutiques, Toulouse, France.
Br J Pharmacol. 2013 Feb;168(3):618-31. doi: 10.1111/j.1476-5381.2012.02231.x.
ρ-Da1a, a 65 amino-acid peptide, has subnanomolar affinity and high selectivity for the human α(1) (A) -adrenoceptor subtype. The purpose of this study was to characterize the pharmacological effects of ρ-Da1a on prostatic function, both in vivo and in vitro.
ρ-Da1a was tested as an antagonist of adrenaline-induced effects on COS cells transfected with the human α(1) (A) -adrenoceptor as well as on human isolated prostatic adenoma obtained from patients suffering from benign prostatic hyperplasia. Moreover, we compared the effects of ρ-Da1a and tamsulosin on phenylephrine (PHE)-induced increases in intra-urethral (IUP) and arterial pressures (AP) in anaesthetized rats, following i.v. or p.o. administration.
On COS cells expressing human α(1) (A) -adrenoceptors and on human prostatic strips, ρ-Da1a inhibited adrenaline- and noradrenaline-induced effects. In anaesthetized rats, ρ-Da1a and tamsulosin administered i.v. 30 min before PHE significantly antagonized the effects of PHE on IUP. The pK(B) values for tamsulosin and ρ-Da1a for this effect were similar. With regards to AP, ρ-Da1a only reduced the effect of PHE on AP at the lowest dose tested (10 μg·kg(-1) ), whereas tamsulosin significantly reduced PHE effects at doses between 10 and 150 μg·kg(-1) .
ρ-Da1a exhibited a relevant effect on IUP and a small effect on AP. In contrast, tamsulosin antagonized the effects of PHE on both IUP and AP. We conclude that ρ-Da1a is more uroselective than tamsulosin. ρ-Da1a is the most selective peptidic antagonist for α(1A) -adenoceptors identified to date and could be a new treatment for various urological diseases.
ρ-Da1a 是一种 65 个氨基酸的肽,对人α(1)(A) -肾上腺素能受体亚型具有亚纳摩尔亲和力和高选择性。本研究的目的是研究 ρ-Da1a 在体内和体外对前列腺功能的药理学作用。
在转染人α(1)(A) -肾上腺素能受体的 COS 细胞以及从患有良性前列腺增生的患者中分离出的人前列腺腺瘤中,测试 ρ-Da1a 作为肾上腺素诱导作用的拮抗剂。此外,我们比较了 ρ-Da1a 和坦索罗辛对静脉内或口服给药后麻醉大鼠中苯肾上腺素 (PHE) 引起的尿道内压 (IUP) 和动脉压 (AP) 升高的影响。
在表达人α(1)(A) -肾上腺素能受体的 COS 细胞和人前列腺条上,ρ-Da1a 抑制肾上腺素和去甲肾上腺素诱导的作用。在麻醉大鼠中,静脉内给予 ρ-Da1a 和坦索罗辛 30 分钟后,可显著拮抗 PHE 对 IUP 的作用。坦索罗辛和 ρ-Da1a 的 pK(B) 值对于这种作用是相似的。对于 AP,只有在最低剂量 (10μg·kg(-1)) 时,ρ-Da1a 才会降低 PHE 对 AP 的作用,而坦索罗辛在 10 至 150μg·kg(-1) 之间的剂量下显著降低 PHE 的作用。
ρ-Da1a 对 IUP 有显著作用,对 AP 有较小作用。相比之下,坦索罗辛拮抗 PHE 对 IUP 和 AP 的作用。我们得出结论,ρ-Da1a 比坦索罗辛更具尿选择性。ρ-Da1a 是迄今为止鉴定出的对 α(1A) -肾上腺素能受体最具选择性的肽拮抗剂,可作为各种泌尿科疾病的新治疗方法。